Clinical Study on the Selection of Endoscopic Varicose Disconnection Strategy Based on Natural Portal Shunt with Portal Hypertension

Launched by ZHEJIANG UNIVERSITY · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at different methods to treat gastric varices, which are swollen veins in the stomach that can cause serious bleeding, particularly in patients with liver disease and portal hypertension. The study aims to find out which endoscopic treatments (a minimally invasive procedure using a thin tube with a camera) are most effective at eliminating these varices and preventing future bleeding. Researchers will compare two specific techniques: one using a spring plug and tissue glue, and another using a titanium clip along with the spring plug. They will also look at how much glue is used, how long patients stay in the hospital, and the overall treatment costs.

To participate in this trial, individuals must be at least 18 years old and have a history of liver cirrhosis with previous bleeding episodes. They should also agree to the endoscopic treatment. However, those who have had prior treatments for bleeding, have serious health issues, or are pregnant are not eligible. Participants can expect to undergo the assigned treatment, have follow-up evaluations over six months, and receive additional care if complications arise. This study is important because it aims to provide clearer guidelines for treating gastric varices, improving outcomes for patients with portal hypertension.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old; 2. History of liver cirrhosis and previous portal hypertension bleeding; 3. Endoscopic and abdominal CT evaluation of IGV1 varicose veins and the presence of SPSS; 4. The patient agrees to treatment under EUS
• Exclusion Criteria:
• • 1. Patients who have received treatment for portal hypertension bleeding (including endoscopy, intervention, and surgery) in the past; 2. Patients with critical illness, pregnant patients, immunodeficiency diseases (such as systemic lupus erythematosus), and mental illness; 3. Patients who refuse endoscopic treatment